Sign In
Buy EYEN
$7.56
+0 (+0%)
At Close: Jan 16, 2026
US FDA approves Eyenovia's eye drug, Formosa Pharma says
06:08pm, Monday, 04'th Mar 2024
The U.S. Food and Drug Administration approved Eyenovia's eye drops to reduce inflammation and pain in patients who have undergone eye surgery, Formosa Pharmaceuticals said on Monday.
Eyenovia: Racing Toward The Finish Line
02:45pm, Monday, 26'th Feb 2024
Eyenovia has received FDA approval for its Optejet system, which revolutionizes how eye medications are dosed, resolving limitations and adverse events caused by traditional eye droppers. The company'
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
07:00am, Tuesday, 13'th Feb 2024
Redwood City, California to complement Eyenovia's facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada
07:00am, Tuesday, 16'th Jan 2024
MicroPine, currently in late phase III for pediatric progressive myopia, to complement Eyenovia's commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007
7 Promising Penny Stocks With the Potential to Defy Expectations
08:17am, Friday, 15'th Dec 2023
You know you want it. High-potential penny stocks that is.
Eyenovia, Inc. (EYEN) Q3 2023 Earnings Call Transcript
09:34pm, Monday, 13'th Nov 2023
Eyenovia, Inc. (NASDAQ:EYEN ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Glenn Garmont - LifeSci Partners, IR Michael Rowe - Chief Executive Officer John Gandol
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
04:05pm, Monday, 13'th Nov 2023
Acquired U.S. commercial rights to APP13007, currently under FDA review for post-surgical ocular pain and inflammation, from Formosa Pharmaceuticals
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
08:16am, Thursday, 09'th Nov 2023
Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.
Eyenovia to Report Third Quarter 2023 Results on Monday, November 13
08:00am, Monday, 06'th Nov 2023
Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT
7 Penny Stocks To Buy Now According To Analysts, Targets Up To 751%
11:32am, Thursday, 02'nd Nov 2023
The penny stock market is an enticing yet volatile landscape for investors seeking big rewards. While the chance to uncover the next hidden gem before it rockets higher is enticing.
Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®
07:00am, Monday, 09'th Oct 2023
In rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions
Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference
08:00am, Thursday, 21'st Sep 2023
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of AP13007 for
Eyenovia: It Is Now Time To See Positive Results In Their Marketing Efforts
05:08pm, Monday, 28'th Aug 2023
Eyenovia has obtained the first required state pharmacy license from New York, allowing them to obtain the first commercial sale of their drug candidate MydCombi. The company has conducted training se
Eyenovia, Inc. (EYEN) Q2 2023 Earnings Call Transcript
09:24am, Sunday, 13'th Aug 2023
Eyenovia, Inc. (NASDAQ:EYEN ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Eric Ribner - Investor Relations Michael Rowe - Chief Executive Officer John Gandolfo - C
Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
08:00am, Wednesday, 09'th Aug 2023
NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1
